GlassScriptPhysician profile
Richard J Kozeny
NPI 1255319810
$11,585.03
in general payments reported to CMS, 2019-2025
49 companies · $2,376 in 2025
The $2,376 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,369 · 2020: $408 · 2021: $175 · 2022: $1,613 · 2023: $2,432 · 2024: $2,212 · 2025: $2,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,020.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,192.43 | 2019-2025 | |
| Amgen INC. | $1,131.98 | 2019-2025 | Tavneos, Repatha, Otezla |
| Abbvie INC. | $992.00 | 2019-2025 | |
| Lilly USA, LLC | $969.41 | 2019-2025 | Mounjaro, Taltz, Zepbound |
| Janssen Biotech, INC. | $928.08 | 2019-2025 | Tremfya |
| Pfizer INC. | $897.72 | 2019-2025 | |
| Novo Nordisk INC | $807.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $754.53 | 2019-2025 | Airsupra, Farxiga, Saphnelo |
| Ucb, INC. | $573.22 | 2019-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.53 | 2019-2025 | Jardiance, Tradjenta, Cyltezo |
| Janssen Pharmaceuticals, INC | $245.13 | 2019-2022 | |
| Amarin Pharma, INC. | $242.22 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.17 | 2019-2025 | Xifaxan, Ibschek |
| Glaxosmithkline, LLC. | $197.18 | 2019-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $181.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kozeny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.